{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:49:52Z","timestamp":1791244192716,"version":"4.1.0"},"reference-count":191,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81991491"],"award-info":[{"award-number":["81991491"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32070940"],"award-info":[{"award-number":["32070940"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2022L3080"],"award-info":[{"award-number":["2022L3080"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012152","name":"National Postdoctoral Program for Innovative Talents","doi-asserted-by":"publisher","award":["BX20220189"],"award-info":[{"award-number":["BX20220189"]}],"id":[{"id":"10.13039\/501100012152","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["2019RU022"],"award-info":[{"award-number":["2019RU022"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M700115"],"award-info":[{"award-number":["2021M700115"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.apsb.2024.03.027","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T18:17:42Z","timestamp":1711304262000},"page":"2361-2377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy"],"prefix":"10.1016","volume":"14","author":[{"given":"Xiaojing","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4731-3982","authenticated-orcid":false,"given":"Wenjing","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2024.03.027_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.apsb.2024.03.027_bib2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2024.03.027_bib3","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","article-title":"Cancer immunotherapy: it's time to better predict patients' response","volume":"125","author":"Pilard","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2024.03.027_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol Cancer Mol Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib6","article-title":"Bispecific antibodies: from research to clinical application","volume":"12","author":"Ma","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2024.03.027_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41570-020-00241-6","article-title":"The renaissance of chemically generated bispecific antibodies","volume":"5","author":"Szijj","year":"2021","journal-title":"Nat Rev Chem"},{"key":"10.1016\/j.apsb.2024.03.027_bib8","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.apsb.2020.08.010","article-title":"Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy","volume":"10","author":"Zhu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.03.027_bib9","article-title":"Antibody-incorporated nanomedicines for cancer therapy","volume":"34","author":"Wu","year":"2022","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2024.03.027_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1035276","article-title":"Current landscape and future directions of bispecific antibodies in cancer immunotherapy","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2024.03.027_bib11","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1126\/science.132.3441.1770","article-title":"Properties of the major component of a peptic digest of rabbit antibody","volume":"132","author":"Nisonoff","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.apsb.2024.03.027_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/305537a0","article-title":"Hybrid hybridomas and their use in immunohistochemistry","volume":"305","author":"Milstein","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2024.03.027_bib13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/316354a0","article-title":"Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody","volume":"316","author":"Perez","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2024.03.027_bib14","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1073\/pnas.90.14.6444","article-title":"\u201cDiabodies\u201d: small bivalent and bispecific antibody fragments","volume":"90","author":"Holliger","year":"1993","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2024.03.027_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4049\/jimmunol.155.1.219","article-title":"Preferential species-restricted heavy\/light chain pairing in rat\/mouse quadromas. Implications for a single-step purification of bispecific antibodies","volume":"155","author":"Lindhofer","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2024.03.027_bib16","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/s43018-023-00586-z","article-title":"The expanding success of T cell-engaging bispecific antibodies","volume":"4","author":"Bargou","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93842-0","article-title":"Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning","volume":"11","author":"Haber","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2024.03.027_bib18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2024.03.027_bib19","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/ph14111172","article-title":"T cell bispecific antibodies: an antibody-based delivery system for inducing antitumor immunity","volume":"14","author":"Kamakura","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.apsb.2024.03.027_bib20","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+ T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib21","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.ymthe.2021.01.025","article-title":"Immunological synapse predicts effectiveness of chimeric antigen receptor Cells","volume":"29","author":"Xiong","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2024.03.027_bib22","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1038\/s41467-019-10920-8","article-title":"Membrane protein-regulated networks across human cancers","volume":"10","author":"Lin","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2024.03.027_bib23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00281-022-00966-0","article-title":"Tumor microenvironment antigens","volume":"45","author":"Andersen","year":"2023","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.apsb.2024.03.027_bib25","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s43018-023-00588-x","article-title":"The landscape of T cell antigens for cancer immunotherapy","volume":"4","author":"Peri","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib26","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.1038\/s41467-021-26367-9","article-title":"Intracellular delivery of protein drugs with an autonomously lysing bacterial system reduces tumor growth and metastases","volume":"12","author":"Raman","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2024.03.027_bib27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","volume":"22","author":"Pishesha","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2024.03.027_bib28","first-page":"22","article-title":"T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins","volume":"2","author":"Xu","year":"2019","journal-title":"Antib Ther"},{"key":"10.1016\/j.apsb.2024.03.027_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13046-022-02474-3","article-title":"Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in\u00a0vitro and in\u00a0vivo","volume":"41","author":"Passariello","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib31","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3390\/cancers11070971","article-title":"Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma","volume":"11","author":"Damato","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.apsb.2024.03.027_bib32","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2024.03.027_bib34","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.beha.2017.09.002","article-title":"Cytokine release syndrome: who is at risk and how to treat","volume":"30","author":"Frey","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.apsb.2024.03.027_bib35","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2165\/11209040-000000000-00000","article-title":"Catumaxomab: in malignant ascites","volume":"72","author":"Frampton","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2024.03.027_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1441","article-title":"JAK1\/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid-derived suppressor cells via the JAK\/STAT and ROS\u2013MAPK\/NF-\u03baB signalling pathways in acute graft-versus-host disease","volume":"12","author":"Cao","year":"2023","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.apsb.2024.03.027_bib37","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1038\/s41467-022-32952-3","article-title":"Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours","volume":"13","author":"Sano","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2024.03.027_bib38","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-CT111","article-title":"Abstract CT111: results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3)\/CD3 bispecific antibody, in patients with advanced solid tumors","volume":"81","author":"Safran","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal4291","article-title":"An anti-glypican 3\/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors","volume":"9","author":"Ishiguro","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib41","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib42","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2024.03.027_bib43","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1080\/10428194.2021.1953016","article-title":"Glofitamab CD20-TCB bispecific antibody","volume":"62","author":"Minson","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.apsb.2024.03.027_bib44","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib45","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib46","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib47","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib48","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102189","article-title":"Neurological complications of cancer immunotherapy","volume":"97","author":"Roth","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.apsb.2024.03.027_bib50","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib51","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for pH-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib52","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib53","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib54","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2024.03.027_bib55","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2024.03.027_bib56","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.apsb.2024.03.027_bib57","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib58","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib59","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib60","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00277-018-3497-0","article-title":"Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors","volume":"98","author":"Stein","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.apsb.2024.03.027_bib61","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2024.03.027_bib62","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.766275","article-title":"Deciphering tumor niches: lessons from solid and hematological malignancies","volume":"12","author":"Mancini","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2024.03.027_bib64","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/cancers13020284","article-title":"Hematopoietic versus solid cancers and T cell dysfunction: looking for similarities and distinctions","volume":"13","author":"Montironi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.apsb.2024.03.027_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","article-title":"Myeloid immunosuppression and immune checkpoints in the tumor microenvironment","volume":"17","author":"Nakamura","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2024.03.027_bib66","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib67","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13046-020-01586-y","article-title":"Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy","volume":"39","author":"Galli","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","article-title":"Mechanisms of immune activation and regulation: lessons from melanoma","volume":"22","author":"Kalaora","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.622509","article-title":"Exhausted CD8+ T cells in the tumor immune microenvironment: new pathways to therapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2024.03.027_bib70","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41571-021-00562-5","article-title":"Tumour antigen-induced T cell exhaustion\u2014the archenemy of immune-hot malignancies","volume":"18","author":"Lopez de Rodas","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib71","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41416-022-02119-4","article-title":"Tumour-infiltrating lymphocytes: from prognosis to treatment selection","volume":"128","author":"Brummel","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib72","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib73","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2024.03.027_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93842-0","article-title":"Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning","volume":"11","author":"Haber","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2024.03.027_bib75","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nri3839","article-title":"Perforin and granzymes: function, dysfunction and human pathology","volume":"15","author":"Voskoboinik","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2024.03.027_bib76","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1038\/s41467-021-25282-3","article-title":"Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity","volume":"12","author":"Weigelin","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2024.03.027_bib77","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib78","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2115205","article-title":"Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy","volume":"14","author":"Xie","year":"2022","journal-title":"mAbs"},{"key":"10.1016\/j.apsb.2024.03.027_bib79","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.apsb.2024.03.027_bib80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.apsb.2024.03.027_bib81","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2024.03.027_bib82","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2024.03.027_bib83","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib84","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib85","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib86","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib87","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.apsb.2024.03.027_bib88","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2024.03.027_bib89","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.molimm.2015.01.024","article-title":"ImmTACs for targeted cancer therapy: why, what, how, and which","volume":"67","author":"Oates","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.apsb.2024.03.027_bib90","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2024.03.027_bib91","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/blood-2021-153355","article-title":"A phase 1 dose escalation study of Igm-2323, a novel anti-CD20\u00a0\u00d7\u00a0anti-CD3 IgM T cell engager (TCE) in patients with advanced B-cell malignancies","volume":"138","author":"Budde","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib92","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-135839","article-title":"Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a phase I dose-escalation trial","volume":"136","author":"Assouline","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib93","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-136044","article-title":"Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib94","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib95","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-136255","article-title":"Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma","volume":"136","author":"Olszewski","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib96","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-136295","article-title":"Mosunetuzumab, a novel CD20\/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma","volume":"136","author":"Phillips","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib97","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1158\/1078-0432.CCR-20-3770","article-title":"Bispecific immunomodulatory antibodies for cancer immunotherapy","volume":"27","author":"Blanco","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib98","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s10020-018-0051-4","article-title":"Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics","volume":"24","author":"Runcie","year":"2018","journal-title":"Mol Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib99","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/d41573-020-00164-3","article-title":"Trispecific antibodies take to the clinic","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2024.03.027_bib100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2019","journal-title":"Nature Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib101","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/d41586-019-03495-3","article-title":"Trispecific antibodies offer a third way forward for anticancer immunotherapy","volume":"575","author":"Garfall","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2024.03.027_bib102","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","article-title":"Bispecific antibodies in cancer therapy: target selection and regulatory requirements","volume":"13","author":"Sun","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.03.027_bib103","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2024.03.027_bib104","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy","volume":"57","author":"Goebeler","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.apsb.2024.03.027_bib105","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib106","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"Swog 1318: a phase II Trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib107","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ctrv.2018.04.002","article-title":"Bispecific antibodies in haematological malignancies","volume":"65","author":"Viardot","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.apsb.2024.03.027_bib108","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-017-0522-z","article-title":"Recent advances of bispecific antibodies in solid tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib109","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/molecules21010042","article-title":"The prodrug approach: a successful tool for improving drug solubility","volume":"21","author":"Jornada","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2024.03.027_bib110","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1078-0432.CCR-19-1457","article-title":"Probody therapeutics: an emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology","volume":"26","author":"Autio","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib111","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12929-020-00652-z","article-title":"Ab locks for improving the selectivity and safety of antibody drugs","volume":"27","author":"Lin","year":"2020","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.apsb.2024.03.027_bib112","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: regulators of the tumor microenvironment","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2024.03.027_bib113","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1158\/1538-7445.AM2022-2869","article-title":"Abstract 2869: ADG138, a novel HER2\u00d7CD3 POWERbody\u2122 integrating bispecific TCE with precision masking to control cytokine release syndrome and on-target off-tumor toxicity for single agent and combination therapies in HER2-expressing solid tumors","volume":"82","author":"Liu","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib114","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1158\/0008-5472.CAN-21-2483","article-title":"A probody T cell-engaging bispecific antibody targeting EGFR and CD3 inhibits colon cancer growth with limited toxicity","volume":"82","author":"Boustany","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib115","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.3390\/ijms23105686","article-title":"Bispecific antibody-based immune-cell engagers and their emerging therapeutic targets in cancer immunotherapy","volume":"23","author":"Shin","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2024.03.027_bib116","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/eji.202048953","article-title":"Natural killer cell engagers in cancer immunotherapy: next generation of immuno-oncology treatments","volume":"51","author":"Demaria","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.apsb.2024.03.027_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2020.100870","article-title":"NK cells and ILCs in tumor immunotherapy","volume":"80","author":"Sivori","year":"2021","journal-title":"Mol Aspect Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib118","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.3389\/fimmu.2019.03013","article-title":"Exploiting human NK cells in tumor therapy","volume":"10","author":"Vacca","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2024.03.027_bib119","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-015-0188-3","article-title":"AFM13: a first-in-class tetravalent bispecific anti-CD30\/CD16A antibody for NK cell-mediated immunotherapy","volume":"8","author":"Wu","year":"2015","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib120","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","article-title":"Combining AFM13, a bispecific CD30\/CD16 antibody, with cytokine-activated blood and cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies","volume":"27","author":"Kerbauy","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib121","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib122","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2019004701","article-title":"A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"136","author":"Bartlett","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib123","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.apsb.2024.03.027_bib124","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/1535-7163.MCT-17-0657","article-title":"Relative target affinities of T cell-dependent bispecific antibodies determine biodistribution in a solid tumor mouse model","volume":"17","author":"Mandikian","year":"2018","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2024.03.027_bib125","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-16-0666","article-title":"MGD011, A CD19\u00a0\u00d7\u00a0CD3 dual-affinity retargeting Bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib126","article-title":"Attenuating CD3 affinity in a PSMA\u00d7CD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release","volume":"19","author":"Dang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib127","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41586-022-05673-2","article-title":"Reducing affinity as a strategy to boost immunomodulatory antibody agonism","volume":"614","author":"Yu","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2024.03.027_bib128","first-page":"90","article-title":"An optimal antitumor response by a novel CEA\/CD3 bispecific antibody for colorectal cancers","volume":"4","author":"Wang","year":"2021","journal-title":"Antib Ther"},{"key":"10.1016\/j.apsb.2024.03.027_bib129","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133757","article-title":"Target arm affinities determine preclinical efficacy and safety of anti-HER2\/CD3 bispecific antibody","volume":"5","author":"Staflin","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.apsb.2024.03.027_bib130","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood-2016-08-735365","article-title":"An anti-CD3\/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia","volume":"129","author":"Leong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib131","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cpt.1961","article-title":"Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology","volume":"108","author":"Betts","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.apsb.2024.03.027_bib132","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1158\/1078-0432.CCR-15-1696","article-title":"A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors","volume":"22","author":"Bacac","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib133","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/19420862.2015.1022694","article-title":"Fab-based bispecific antibody formats with robust biophysical properties and biological activity","volume":"7","author":"Wu","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.apsb.2024.03.027_bib134","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.tips.2018.12.002","article-title":"Emerging structure\u2013function paradigm of endocrine FGFs in metabolic diseases","volume":"40","author":"Luo","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2024.03.027_bib135","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2021-150519","article-title":"Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from magnetismm-1","volume":"138","author":"Sebag","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib136","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.3390\/cancers14102518","article-title":"Bispecific BCMA-CD3 antibodies block multiple myeloma tumor growth","volume":"14","author":"Wu","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.apsb.2024.03.027_bib137","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1078-0432.CCR-20-2150","article-title":"A self-assembling and disassembling (SADA) bispecific antibody (BsAb) platform for curative two-step pretargeted radioimmunotherapy","volume":"27","author":"Santich","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib138","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/CCO.0000000000000983","article-title":"T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA","volume":"35","author":"van de Donk","year":"2023","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib139","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/mt.2013.240","article-title":"T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy","volume":"22","author":"Yu","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2024.03.027_bib141","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1158\/1535-7163.MCT-21-0073","article-title":"Targeting solid tumors using CD3 bispecific antibodies","volume":"20","author":"Crawford","year":"2021","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2024.03.027_bib142","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/cbdd.14116","article-title":"DNA intercalators as anticancer agents","volume":"100","author":"Venugopal","year":"2022","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.apsb.2024.03.027_bib143","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/1568009619666191007112516","article-title":"Natural DNA intercalators as promising therapeutics for cancer and infectious diseases","volume":"20","author":"Godzieba","year":"2020","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.apsb.2024.03.027_bib144","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12943-022-01680-z","article-title":"Biological and pharmacological roles of m6A modifications in cancer drug resistance","volume":"21","author":"Liu","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib145","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.tips.2019.03.003","article-title":"Rethinking alkylating(-like) agents for solid tumor management","volume":"40","author":"Lajous","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2024.03.027_bib146","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3389\/fonc.2020.01256","article-title":"The therapeutic potential of DNA damage repair pathways and genomic stability in lung cancer","volume":"10","author":"Burgess","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib147","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-016-3152-1","article-title":"The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy","volume":"78","author":"Ahlmann","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.apsb.2024.03.027_bib148","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib149","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1078-0432.CCR-06-1209","article-title":"Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration","volume":"13","author":"Bracci","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib150","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.apsb.2024.03.027_bib151","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","article-title":"Avidity in antibody effector functions and biotherapeutic drug design","volume":"21","author":"Oostindie","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2024.03.027_bib152","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody\u2013drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.apsb.2024.03.027_bib153","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody\u2013drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.apsb.2024.03.027_bib154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21873\/anticanres.14746","article-title":"Chemoradiotherapy in cancer treatment: rationale and clinical applications","volume":"41","author":"Rallis","year":"2021","journal-title":"Anticancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib155","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2024.03.027_bib156","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/biom12030358","article-title":"Anti-GD2 directed immunotherapy for high-risk and metastatic neuroblastoma","volume":"12","author":"Chan","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.apsb.2024.03.027_bib157","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002923","article-title":"GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma","volume":"9","author":"Zirngibl","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib158","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1158\/1535-7163.MCT-15-0156","article-title":"Efficacy and tolerability of a GD2-directed trifunctional bispecific antibody in a preclinical model: subcutaneous administration is superior to intravenous delivery","volume":"14","author":"Deppisch","year":"2015","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2024.03.027_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101366","article-title":"Radiotherapy: brightness and darkness in the era of immunotherapy","volume":"19","author":"Zhai","year":"2022","journal-title":"Transl Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib160","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2024.03.027_bib161","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2024.03.027_bib162","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib163","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2024.03.027_bib164","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib165","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2096362","article-title":"Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer","volume":"11","author":"Wang","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.apsb.2024.03.027_bib166","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1158\/1078-0432.CCR-17-2651","article-title":"Targeted BiTE expression by an oncolytic vector augments therapeutic efficacy against solid tumors","volume":"24","author":"Speck","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib167","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003766","article-title":"JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in\u00a0vivo efficacy","volume":"10","author":"Leclercq","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib168","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","article-title":"Bruton tyrosine kinase inhibitors: present and future","volume":"25","author":"Burger","year":"2019","journal-title":"Cancer J"},{"key":"10.1016\/j.apsb.2024.03.027_bib169","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib170","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1182\/blood.2020009686","article-title":"BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19\/CD3-bispecific antibody in CLL","volume":"138","author":"Mhibik","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.03.027_bib171","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2024.03.027_bib172","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in\u00a0vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib-findings from an investigator-initiated phase II study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2024.03.027_bib173","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/leu.2017.304","article-title":"Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1\/PDL1 pathway","volume":"32","author":"Kondo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2024.03.027_bib174","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/hon.2667","article-title":"The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"37","author":"Zou","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib175","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-015-0213-6","article-title":"Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab","volume":"8","author":"K\u00f6hnke","year":"2015","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib176","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.leu.2403588","article-title":"CTLA-4 overexpression in CD191\/CD51 cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients","volume":"19","author":"Kosmaczewska","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2024.03.027_bib177","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd1524","article-title":"Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors","volume":"13","author":"Belmontes","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib178","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2147\/PPA.S296747","article-title":"Adherence to adjuvant tamoxifen in mexican young women with breast cancer","volume":"15","author":"Martinez-Cannon","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.apsb.2024.03.027_bib179","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jconrel.2023.01.041","article-title":"Microenvironment-responsive anti-PD-L1\u00a0\u00d7\u00a0CD3 bispecific T-cell engager for solid tumor immunotherapy","volume":"354","author":"Liu","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2024.03.027_bib180","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","article-title":"Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors","volume":"4","author":"Cattaruzza","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.apsb.2024.03.027_bib181","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13045-023-01516-3","article-title":"Development and characterization of NILK-2301, a novel CEACAM5xCD3 \u03ba\u03bb bispecific antibody for immunotherapy of CEACAM5-expressing cancers","volume":"16","author":"Seckinger","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib182","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/antib8030041","article-title":"Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells","volume":"8","author":"Strohl","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.apsb.2024.03.027_bib183","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax8861","article-title":"CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib184","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2024.03.027_bib185","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/697972","article-title":"Monocytes, peripheral blood mononuclear cells, and THP-1 cells exhibit different cytokine expression patterns following stimulation with lipopolysaccharide","volume":"2013","author":"Schildberger","year":"2013","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.apsb.2024.03.027_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114657","article-title":"Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy","volume":"379","author":"Iwata","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.apsb.2024.03.027_bib187","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","article-title":"Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies","volume":"11","author":"Trinklein","year":"2019","journal-title":"mAbs"},{"key":"10.1016\/j.apsb.2024.03.027_bib188","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3389\/fonc.2020.00446","article-title":"Perspective: designing T-cell engagers with better therapeutic windows","volume":"10","author":"Vafa","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2024.03.027_bib189","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","article-title":"T cell engaging bispecific antibody (T-cell redirecting BsAb): from technology to therapeutics","volume":"182","author":"Wu","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2024.03.027_bib190","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00404-016-4036-7","article-title":"Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue","volume":"294","author":"Peters","year":"2016","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.apsb.2024.03.027_bib191","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2019.1682866","article-title":"Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironment","volume":"12","author":"Sulea","year":"2020","journal-title":"mAbs"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524001084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524001084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T12:11:22Z","timestamp":1716811882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383524001084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":191,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2211383524001084"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2024.03.027","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2024.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}